

# Zhenhua Ren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3621673/publications.pdf>

Version: 2024-02-01

16  
papers

894  
citations

759233  
12  
h-index

888059  
17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1493  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell, 2021, 39, 96-108.e6.	16.8	153
2	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	12.8	132
3	Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis. Cancer Cell, 2019, 35, 901-915.e4.	16.8	98
4	Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion. Cell Reports, 2018, 24, 2101-2111.	6.4	90
5	Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nature Immunology, 2020, 21, 546-554.	14.5	78
6	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell, 2020, 38, 400-411.e6.	16.8	70
7	Targeting IFNÎ± to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	12.8	60
8	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Cancer Discovery, 2016, 6, 477-478.	9.4	41
9	Dual targeting of CTLA-4 and CD47 on T <sub>reg</sub> cells promotes immunity against solid tumors. Science Translational Medicine, 2021, 13, .	12.4	39
10	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	8.2	38
11	CTLA-4 Limits Anti-CD20â€ Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	7.0	35
12	Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity. Science Immunology, 2019, 4, .	11.9	30
13	ZMYND8 Expression in Breast Cancer Cells Blocks T-Lymphocyte Surveillance to Promote Tumor Growth. Cancer Research, 2021, 81, 174-186.	0.9	12
14	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunology Research, 2017, 5, 560-570.	3.4	10
15	Degradation of CTLA-4 balances toxicity and efficacy. Science Bulletin, 2019, 64, 1388-1389.	9.0	2
16	Abstract 973: Telomere stress potentiates host STING-dependent anti-tumor immunity. , 2020, , .		0